The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -2,344 | -9,503 |
| Depreciation and amortization | 528 | 1,060 |
| Stock-based compensation | 70 | 189 |
| Change in fair value of royalties payable due to related parties | 726 | -2,830 |
| Change in fair value of trading debt securities | 107 | 10 |
| Deferred income tax benefit | 78 | -1,674 |
| Acquired in-process research and development | 0 | 1,967 |
| Amortization of discount on note payable | 17 | 10 |
| Accounts receivable | 8 | 45 |
| Inventories | -4 | 25 |
| Prepaid expenses and other current assets | 83 | -145 |
| Operating lease right-of-use assets and lease liabilities | -1 | -4 |
| Current portion of royalties payable due to related parties | -7 | 14 |
| Accounts payable | 303 | 361 |
| Accrued expenses | 30 | -15 |
| Interest payable-Related Party | 48 | 90 |
| Interest payable-Variable Interest Entity Not Primary Beneficiary | 15 | 9 |
| Net cash used in operating activities | -2,183 | -4,601 |
| Purchases of acquired in-process research and development | 28 | 6 |
| Purchases of property and equipment | 0 | 17 |
| Net cash used in investing activities | -28 | -23 |
| Proceeds from issuance of series b convertible preferred stock and other equity-classified warrants, net of issuance costs-Series BConvertible Preferred Stock | 0 | 1,170 |
| Proceeds from issuance of common stock and other equity-classified contracts from the september 2024 public offering, net of issuance costs-September2024Public Offering | 0 | - |
| Proceeds from issuance of common stock and other equity-classified contracts from the september 2024 public offering, net of issuance costs | 2,174 | 1,570 |
| Proceeds from notes payable due to related parties | 300 | 0 |
| Payments on notes payable | 26 | 151 |
| Payments on deferred financing costs | - | 0 |
| Proceeds from notes payable | 0 | - |
| Net cash provided by financing activities | 2,448 | 2,589 |
| Net change in cash and cash equivalents | 237 | -2,035 |
| Cash and cash equivalents at beginning of period | 2,873 | - |
| Cash and cash equivalents at end of period | 1,075 | - |
Catheter Precision, Inc. (VTAK)
Catheter Precision, Inc. (VTAK)